Are You Overpaying For Merck Stock Versus Its Rivals?
Merck (MRK) stock has returned 76.4% over the past twelve months, the most in a group of six drugmakers that includes Eli Lilly, Johnson & Johnson, and Pfizer. A run like that suggests buyers believe Merck’s business is pulling ahead of its rivals, or soon will. So how does Merck’s business rank against those same […]